Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Outset Medical, Inc. (NASDAQ: OM) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. Outset is a medical technology manufacturer focused on the Tablo Hemodialysis System, and its filings offer detail on financial performance, risk factors, and the business model behind its dialysis platform.
Among the key documents, investors can review Form 10-K annual reports and Form 10-Q quarterly reports, which typically include discussions of product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and liquidity. These filings also reference the risks and uncertainties that could affect Outset’s results and the regulatory environment in which it operates.
Outset’s Form 8-K current reports are particularly relevant for tracking material events. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter financial results and updated or revised revenue guidance. Such filings summarize the nature of the event and incorporate the related press release by reference.
On this page, users can also monitor insider transaction reports on Form 4, proxy statements on Schedule 14A when available, and other submissions that shed light on governance, executive compensation, and ownership changes.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy documents, highlight notable changes from prior periods, and surface items such as revenue mix, margin commentary, and forward-looking statements. Real-time updates from EDGAR help ensure that new OM filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider reports, are quickly reflected and summarized for easier review.
Outset Medical, Inc. reported that it issued a press release with expected revenue for the fourth quarter and full year ended December 31, 2025, noting that this financial information is preliminary, unaudited and may change as closing and audit processes are completed. The company also furnished an updated investor presentation.
Board member Andrea Saia resigned effective January 9, 2026, and the company stated her departure was not due to any disagreement on operations, policies or practices. The Board appointed Karen Prange as a new independent director and Compensation Committee member, filling the vacancy as a class III director with a term running until the 2026 annual meeting. In connection with her appointment, Prange will receive an initial grant of 18,667 restricted stock units that vest quarterly over three years and an annual grant of 10,667 restricted stock units, subject to the company’s non‑employee director compensation policy.
Outset Medical executive Marc Nash reported a small, tax-related stock sale. On January 7, 2026, he sold 108 shares of Outset Medical common stock at $4.27 per share.
According to the footnote, the sale was required to cover tax withholding obligations tied to 289 shares underlying performance stock units that were earned based on performance criteria as of December 31, 2024 or January 6, 2025 and that vested and were released on January 6, 2025. The transaction was executed as a "sell to cover" and is described as not a discretionary trade by Nash.
After this sale, Nash directly beneficially owns 48,160 shares of Outset Medical common stock.
Outset Medical, Inc. reported that its General Counsel, John L. Brottem, sold 224 shares of common stock on 01/07/2026 at a price of $4.27 per share. After this transaction, he beneficially owned 46,271 shares directly.
The filing explains that the sale was a required "sell to cover" transaction to satisfy tax withholding obligations tied to 447 shares of common stock underlying performance stock units that had been earned and vested, and it did not represent a discretionary trade by Brottem.
Outset Medical, Inc. Chair and CEO Leslie Trigg reported a small sale of company stock that was made only to cover taxes. On January 7, 2026, she sold 1,795 shares of common stock at $4.27 per share in a transaction coded “S,” described as a “sell to cover” for tax withholding related to previously earned PSUs. According to the disclosure, this sale was required to satisfy tax obligations and “does not represent a discretionary trade.”
Following the sale, Trigg beneficially owned 119,617 shares of common stock directly, plus 41,666 shares held indirectly through the Trigg 2002 Rev Trust and 584 shares held indirectly through the Trigg Family Trust.
OM filed a Rule 144 notice for a small planned stock sale. The filing covers the proposed sale of 108 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC on or about 01/07/2026, with the shares listed for trading on NASDAQ. The aggregate market value of this planned sale is reported as $461.16, based on market prices at the time of the notice.
The seller acquired the stock on 01/06/2026 through settlement of 289 vested performance stock units from the issuer as equity compensation for services rendered. Over the prior three months, the same seller disposed of 247 common shares on 11/17/2025 for gross proceeds of $1,136.20. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about OM’s current or prospective operations.
OM insider Leslie Trigg filed a notice of proposed sale of common stock under Rule 144. The filing covers the planned sale of 1,795 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $7,664.65 and 18,153,090 shares of common stock shown as outstanding.
The shares to be sold are part of a larger 4,904-share grant of common stock acquired on 01/06/2026 via settlement of vested performance stock units as equity compensation for services rendered. The filing also notes that Trigg previously sold 916 shares of common stock on 11/17/2025 for gross proceeds of $4,213.60. By signing, the seller represents they are not aware of undisclosed material adverse information about OM.
OM insider John Brottem filed a Rule 144 notice to sell 224 shares of common stock through Morgan Stanley Smith Barney LLC on approximately 01/07/2026, with an aggregate market value of $956.48 on the NASDAQ exchange. The filing notes that 18,153,090 shares of common stock were outstanding.
The shares to be sold come from 447 common shares acquired on 01/06/2026 via settlement of vested performance stock units as equity compensation for services rendered. The notice also reports that Brottem previously sold 388 shares of common stock on 11/17/2025 for gross proceeds of $1,784.80, and includes a representation that he is not aware of undisclosed material adverse information about OM.
Outset Medical, Inc. (OM) reported an insider transaction by its Chair and CEO, Leslie Trigg. On 11/17/2025, Trigg sold 916 shares of common stock at $4.60 per share in a transaction coded “S.” The company notes this was a required sale to cover tax withholding tied to the vesting of 1,770 shares of common stock underlying restricted stock units granted on January 6, 2023 and January 12, 2024, and it did not represent a discretionary trade. After the transaction, Trigg beneficially owned 121,412 shares directly and additional shares indirectly through the Trigg 2002 Rev Trust and the Trigg Family Trust.
Outset Medical, Inc. (OM) reported an insider share sale by its EVP Operations R&D & Service, Marc Nash. On 11/17/2025, Nash sold 247 shares of common stock at $4.60 per share in a transaction coded "S," leaving him with 48,268 shares beneficially owned. The company explains that the shares were sold solely to cover tax withholding obligations tied to the vesting of 674 shares of common stock underlying RSUs granted on March 15, 2023, July 24, 2023, and January 12, 2024, and that the sale did not represent a discretionary trade by Nash.
Outset Medical, Inc. reported an insider transaction by its General Counsel, John L. Brottem. On 11/17/2025, he sold 388 shares of common stock at $4.6 per share. The sale was required to cover tax withholding obligations tied to the vesting of 748 shares of common stock underlying restricted stock units granted on January 6, 2023 and January 12, 2024, and is described as a non-discretionary "sell to cover" transaction. After this trade, he directly holds 46,495 shares of Outset Medical common stock.